List of chemotherapy regimens: Difference between revisions

Jump to navigation Jump to search
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{SI}}
{{Seealso|List of chemotherapeutic agents}}
{{Seealso|List of chemotherapeutic agents}}
{{CMG}}; {{AE}} Ross Bonander
{{CMG}}; {{AE}} {{AV}}


==Overview==
==Overview==
Line 8: Line 7:


==List of Chemotherapy Regimens==
==List of Chemotherapy Regimens==
{| class="wikitable"
{| style="font-weight: bold;"
! Name !! Components !! Example of uses, and other notes
! style="font-size: 85%; background: #545454; color: #F8F8FF;" | Regimen
! style="font-size: 85%; background: #545454; color: #F8F8FF;" | Indications
|-
|-
| '''[[7+3 regimen|7+3]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[7+3 regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
| 7 days of Ara-C ([[cytarabine]]) plus 3 days of an [[anthracycline]] [[antibiotic]], either [[daunorubicin]] ([[DA regimen|DA]] or [[DAC regimen|DAC]] variant) or [[idarubicin]] ([[IA regimen|IA]] or [[IAC regimen|IAC]] variant)
| [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
|-
|-
| '''[[ABVD]]''' <ref name="pmid54209">{{cite journal |author=Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C |title=Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP |journal=Cancer |volume=36 |issue=1 |pages=252–9 |year=1975 |month=July |pmid=54209 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ABVD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Adriamycin]], [[bleomycin]], [[vinblastine]], [[dacarbazine]]
| [[Hodgkin's lymphoma]]
|-
|-
|'''ABVE-PC''' <ref name="pmid19584400">{{cite journal |author=Schwartz CL, Constine LS, Villaluna D, ''et al.'' |title=A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425 |journal=Blood |volume=114 |issue=10 |pages=2051–9 |year=2009 |month=September |pmid=19584400 |doi=10.1182/blood-2008-10-184143 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ABVE-PC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Doxorubicin]], bleomycin, vincristine, etoposide, prednisone, cyclophosphamide
| Pediatric Hodgkin's lymphoma
|-
|-
| '''AC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[AC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
| [[Adriamycin]]/[[Doxorubicin]], [[Cyclophosphamide]]
| [[Breast cancer]]
|-
|-
| '''[[ACVBP-R regimen|ACVBP-R]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ACVBP-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Adriamycin]], [[Cytoxan]], [[Vindesine]], [[Bleomycin]], [[Prednisone]], [[Rituximab]]
| [[Diffuse large B-cell lymphoma]]
|-
|-
| '''ADOC''' <ref name="pmid10555755">{{cite journal |author=Berruti A, Borasio P, Gerbino A, ''et al.'' |title=Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience |journal=Br. J. Cancer |volume=81 |issue=5 |pages=841–5 |year=1999 |month=November |pmid=10555755 |pmc=2374302 |doi=10.1038/sj.bjc.6690773 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ADOC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Thymoma
| [[Doxorubicin]], [[cisplatin]], [[vincristine]], [[cyclophosphamide]]
| [[Thymic carcinoma]]
|-
|-
| '''BACOD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[BACOD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Bleomycin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[dexamethasone]]
| [[Non-Hodgkin's lymphoma]]
|-
|-
| '''[[BEACOPP]]''' <ref name="pmid9850026">{{cite journal |author=Diehl V, Franklin J, Hasenclever D, ''et al.'' |title=BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group |journal=J. Clin. Oncol. |volume=16 |issue=12 |pages=3810–21 |year=1998 |month=December |pmid=9850026 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[BEACOPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Bleomycin]], [[etoposide]], [[Adriamycin]] ([[doxorubicin]]), [[cyclophosphamide]], [[Oncovin]] ([[vincristine]]), [[procarbazine]], [[prednisone]]
| [[Hodgkin's lymphoma]]
|-
|-
| '''BEP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[BEP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Ovarian and testicular germ-cell tumors
| [[Bleomycin]], [[etoposide]], platinum ([[cisplatin]])
| [[Testicular cancer]], [[germ cell tumor]]s
|-
|-
| '''CA'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
| [[cyclophosphamide]], [[doxorubicin]] (Adriamycin) (same as AC)
| [[Breast cancer]]
|-
|-
| '''CAF'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CAF regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[5-FU]]/[[Fluorouracil]]
| [[Breast cancer]]
|-
|-
| '''CAPOX'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CAPOX regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colorectal cancer
| [[Capecitabine]] and [[oxaliplatin]]
| [[Colorectal cancer]]
|-
|-
| '''CAV'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CAV regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Small cell lung cancer
| [[Cyclophosphamide]], [[Adriamycin]]/[[Doxorubicin]], [[Vincristine]]
| [[Lung cancer]]
|-
|-
| '''CBV'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CBV regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute leukemia
| [[Cyclophosphamide]], [[BCNU|BCNU (carmustine)]], VP-16 ([[etoposide]])
| [[Lymphoma]]
|-
|-
| '''CEOP-R'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CDOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Cyclophosphamide]], [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]] + rituximab
| [[Diffuse large B-cell lymphoma]] when patient cannot be given an anthracycline 
|-
|-
| '''CEPP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CEOP-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Cyclophosphamide]], [[etoposide]], [[procarbazine]], [[prednisone]]
| [[Non-Hodgkin's lymphoma]]
|-
|-
| '''ChlVPP/EVA'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CEPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Chlorambucil]], [[vincristine]] (Oncovin), [[procarbazine]], [[prednisone]], [[etoposide]], [[vinblastine]], [[doxorubicin]] (Adriamycin)
| [[Hodgkin's lymphoma]]
|-
|-
| '''CHOEP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ChlVPP-EVA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Cyclophosphamide]], hydroxydaunorubicin ([[doxorubicin]]), [[etoposide]], vincristine ([[Oncovin]]), [[prednisone]]
| [[Non-Hodgkin's lymphoma]]
|-
|-
| '''[[CHOP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CHOEP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Cyclophosphamide]], [[doxorubicin]] ([[hydroxydoxorubicin]]), vincristine ([[Oncovin]]), [[prednisone]]
| [[Non-Hodgkin's lymphoma]]
|-
|-
| '''CHOP-R''' or '''R-CHOP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CHOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| CHOP + [[rituximab]]
| [[B cell]] [[non-Hodgkin lymphoma]]
|-
|-
| '''[[CHOP|COP]]''' or '''[[CHOP|CVP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CHOP-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Cyclophosphamide]], [[vincristine]] (Oncovin), and [[prednisone]]
| Non-Hodgkin lymphoma in patients with history of [[cardiovascular disease]]
|-
|-
| '''ClaPD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ClaPD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
| [[Clarithromycin]], [[pomalidomide]], [[dexamethasone]]
| [[Multiple myeloma]]
|-
|-
| '''[[CMF (therapy)|CMF]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CMF regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
| [[Cyclophosphamide]], [[Methotrexate]], and [[5-Fluorouracil]]
| [[Breast Cancer]]
|-
|-
| '''CMV'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CMV regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Bladder carcinoma
| [[Cisplatin]], [[methotrexate]], [[vinblastine]]
| Metastatic [[transitional cell carcinoma]] of the urinary tract
|-
|-
| '''CODOX-M/IVAC''' <ref name="pmid12181251">{{cite journal |author=Mead GM, Sydes MR, Walewski J, ''et al.'' |title=An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study |journal=Ann. Oncol. |volume=13 |issue=8 |pages=1264–74 |year=2002 |month=August |pmid=12181251 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CNOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| Cyclophosphamide, vincristine, doxorubicin, methotrexate (CODOX-M) + ifosfamide, etopiside (VP-16), cytarabine (Ara-C) (IVAC)
| [[Burkitt's lymphoma]]
|-
|-
| '''[[COPP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CODOX-M/IVAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Burkitt's lymphoma
| [[Cyclophosphamide]], Oncovin (vincristine), [[procarbazine]] and prednisone
| [[Non-Hodgkin lymphoma]]
|-
|-
| '''CT''' or '''TC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[COP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Cyclophosphamide]] and [[docetaxel]] (Taxotere)
| [[Breast cancer]]
|-
|-
| '''CTD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[COPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, Non-Hodgkin's lymphoma
| [[Cyclophosphamide]], [[thalidomide]], [[dexamethasone]]
| [[AL amyloidosis]]
|-
|-
| '''CVAD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CT regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Ovarian cancer
| [[Cyclophosphamide]], [[vincristine]], [[doxorubicin]] (Adriamycin), [[dexamethasone]]
| Aggressive [[non-Hodgkin lymphoma]], [[lymphoblastic lymphoma]], some forms of [[leukemia]]
|-
|-
| '''CyBorD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CTD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
| [[Cyclophosphamide]], [[bortezomib]], [[dexamethasone]]
| [[Multiple myeloma]], [[AL amyloidosis]]
|-
|-
| '''DA-EPOCH''' <ref name="pmid11929754">{{cite journal |author=Wilson WH, Grossbard ML, Pittaluga S, ''et al.'' |title=Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy |journal=Blood |volume=99 |issue=8 |pages=2685–93 |year=2002 |month=April |pmid=11929754 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CVAD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
| Dose-adjusted [[Etopiside]], [[prednisone]], [[vincristine]] (Oncovin), [[Cyclophosphamide]] and doxorubicin
| Newly diagnosed, aggressive [[non-Hodgkin lymphoma]]
|-
|-
| '''DCEP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CVP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Dexamethasone]], [[cyclophosphamide]], [[etoposide]], [[platinum-based antineoplastic|platinum agent]]
| [[Multiple myeloma]]
|-
|-
| '''DHAP''' <ref name="pmid3334893">{{cite journal |author=Velasquez WS, Cabanillas F, Salvador P, ''et al.'' |title=Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP) |journal=Blood |volume=71 |issue=1 |pages=117–22 |year=1988 |month=January |pmid=3334893 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[CyBorD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma, AL amyloidosis
| Dexamethasone, cytarabine (high-dose ARA-C), cisplatin
| Recurrent or refractory [[non-Hodgkin lymphoma]]
|-
|-
| '''DHAX-R''' <ref name="pmid20709662">{{cite journal |author=Lignon J, Sibon D, Madelaine I, ''et al.'' |title=Rituximab, Dexamethasone, Cytarabine, and Oxaliplatin (R-DHAX) Is an Effective and Safe Salvage Regimen in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma |journal=Clin Lymphoma Myeloma Leuk |volume=10 |issue=4 |pages=262–9 |year=2010 |month=August |pmid=20709662 |doi=10.3816/CLML.2010.n.055 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DA-EPOCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| Dexamethasone, cytarabine, oxaliplatin and rituximab
| Relapsed or refractory B-cell [[non-Hodgkin lymphoma]]
|-
|-
| '''DICE'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DA-R-EPOCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Dexamethasone]], [[ifosfamide]], [[cisplatin]], [[etoposide]] (VP-16)
| Aggressive relapsed [[lymphomas]], progressive [[neuroblastoma]]
|-
|-
| '''DT-PACE'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DBVE-PC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Dexamethasone]], [[thalidomide]], [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
| [[Multiple myeloma]]
|-
|-
| '''EC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DCEP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
| [[Epirubicin]], [[Cyclophosphamide]]
| [[Breast cancer]]
|-
|-
| '''ECF'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DHAP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, Non-Hodgkin's lymphoma
| [[Epirubicin]], [[cisplatin]], [[fluorouracil]]
| [[Gastric cancer]] and [[oesophageal cancer]]
|-
|-
| '''EOX'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DHAX-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Epirubicin]], [[oxaliplatin]], [[capecitabine]]
| [[Esophageal cancer]], [[gastric cancer]]
|-
|-
| '''EP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DICE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Etoposide]], [[platinum-based antineoplastic|platinum agent]]
| [[testicular cancer]], [[germ cell tumor]]s
|-
|-
| '''EPOCH'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[DT-PACE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple Myeloma
| [[Etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]]
| [[Non-Hodgkin lymphoma]]s
|-
|-
| '''EPOCH-R''' or '''R-EPOCH'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Small cell lung cancer
| [[Etoposide]], [[prednisone]], [[vincristine]] (Oncovin), [[cyclophosphamide]], and [[hydroxydaunorubicin]] plus [[rituximab]]
| [[B cell]] [[Non-Hodgkin lymphoma]]s
|-
|-
| '''ESHAP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ECF regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Gastric cancer
| [[Etopiside]], methylprednisolone (Solu-medrol), cytarabine (ARA-C), cisplatin
| Relapsed or refractory [[non-Hodgkin lymphoma]]
|-
|-
| '''ESHAP-R''' or '''R-ESHAP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EOX regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Oesophageal cancer
| [[etoposide]], [[methylprednisolone]] (a [[steroid hormone]]), [[cytarabine]] (ara-C), [[platinum-based antineoplastic|platinum agent]] plus [[rituximab]]
| [[Non-Hodgkin lymphoma]]
|-
|-
| '''FAM'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Small cell lung cancer
| [[Fluorouracil]], [[doxorubicin]] (Adriamycin), [[mitomycin]]
| Metastatic small bowel adenocarcinoma
|-
|-
| '''FCM''' or '''FMC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EPOCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
|-
| '''FCM-R''' or '''R-FCM''' or '''R-FMC''' or '''FMC-R'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[EPOCH-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Fludarabine]], [[cyclophosphamide]], [[mitoxantrone]] plus [[rituximab]]
| [[B cell]] non-Hodgkin lymphoma
|-
|-
| '''FM'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ESHAP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, Non-Hodgkin's lymphoma
| [[Fludarabine]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
|-
| '''FMR'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ESHAP-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, Non-Hodgkin's lymphoma
| [[Fludarabine]], [[mitoxantrone]], and [[rituximab]]
| [[B cell]] non-Hodgkin lymphoma
|-
|-
| '''FEC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FAM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Gastric cancer, Pancreatic cancer
| [[Fluorouracil]] (5-FU), [[epirubicin]], [[cyclophosphamide]]
| [[Breast cancer]]
|-
|-
| '''FL'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FCM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma, Mantle cell lymphoma
| [[Fluorouracil]] (5-FU), leucovorin ([[folinic acid]])
| [[Colorectal cancer]]
|-
|-
| '''FLAG'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FCM-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Chronic lymphocytic leukemia
| [[Fludarabine]], [[cytarabine]], [[G-CSF]]
| Relapsed or [refractory [[acute myelogenous leukemia]]
|-
|-
| '''FLAG-Ida''' or '''FLAG-IDA''' or '''IDA-FLAG''' or '''Ida-FLAG'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FEC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
| [[Fludarabine]], [[cytarabine]], [[idarubicin]], [[G-CSF]]
| Relapsed or [[refractoriness|refractory]] [[acute myelogenous leukemia]]
|-
|-
| '''FLAG-Mito''' or '''FLAG-MITO''' or '''Mito-FLAG''' or '''MITO-FLAG''' or '''FLAMG'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FL regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colon cancer
| [[Mitoxantrone]], [[fludarabine]], [[cytarabine]], [[G-CSF]]
| Relapsed or refractory [[acute myelogenous leukemia]]
|-
|-
| '''FLAMSA'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAG regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myeloid leukemia
| [[Fludarabine]], [[cytarabine]], [[amsacrine]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
|-
| '''FLAMSA-BU''' or '''FLAMSA-Bu'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAG-Ida regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndromes and Acute myeloid leukaemia
| [[Fludarabine]], [[cytarabine]], [[amsacrine]], [[busulfan]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
|-
| '''FLAMSA-MEL''' or '''FLAMSA-Mel'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAG-Mito regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
| [[Fludarabine]], [[cytarabine]], [[amsacrine]], [[melphalan]]
| [[Myelodysplastic syndrome]], [[acute myeloid leukemia]]
|-
|-
| '''FN-D''' <ref name="pmid8648382">{{cite journal |author=McLaughlin P, Hagemeister FB, Romaguera JE, ''et al.'' |title=Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma |journal=J. Clin. Oncol. |volume=14 |issue=4 |pages=1262–8 |year=1996 |month=April |pmid=8648382 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAMSA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
| Fludarabine, mitoxantrone (Novantrone), dexamethasone
| Recurrent or refractory indolent [[non-Hodgkin lymphoma]]
|-
|-
| '''FOLFIRI''' <ref name="pmid10744089">{{cite journal |author=Douillard JY, Cunningham D, Roth AD, ''et al.'' |title=Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial |journal=Lancet |volume=355 |issue=9209 |pages=1041–7 |year=2000 |month=March |pmid=10744089 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAMSA-BU regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
| Leucovorin, infusional fluorouracil, irinotecan
| Metastatic [[colorectal cancer]]
|-
|-
| '''FOLFIRINOX'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FLAMSA-MEL regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
| [[Fluorouracil]] (5-FU), leucovorin ([[folinic acid]]), [[irinotecan]], [[oxaliplatin]]
| [[Pancreatic cancer]]
|-
|-
| '''[[FOLFOX]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-hodgkin lymphoma
| [[Fluorouracil]], [[leucovorin]] ([[folinic acid]]), and [[oxaliplatin]]
| [[Colorectal cancer]]
|-
|-
| '''GVD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FMC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Chronic lymphocytic leukaemia
| [[Gemcitabine]], [[vinorelbine]], pegylated liposomal [[doxorubicin]]
| [[Hodgkin lymphoma]]
|-
|-
| '''GemOx'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FMC-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin lymphoma, mantle cell lymphoma, CLL
| [[Gemcitabine]], [[oxaliplatin]]
| [[Non-Hodgkin's lymphoma]]
|-
|-
| '''GemOx-R'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FMR regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-hodgkin lymphoma
| [[Gemcitabine]], [[oxaliplatin]], [[rituximab]]
| [[Non-Hodgkin lymphoma]]s
|-
|-
| '''HYPER-CVAD''' <ref name="pmid10561310">{{cite journal |author=Thomas DA, Cortes J, O'Brien S, ''et al.'' |title=Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia |journal=J. Clin. Oncol. |volume=17 |issue=8 |pages=2461–70 |year=1999 |month=August |pmid=10561310 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FN-D regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| Hyperfractionated cyclophosphamide, vincristine (Oncovin), doxorubicin (Adriamycin), dexamethasone ([[Decadron]])
| [[Burkitt's lymphoma]]
|-
|-
| '''IA''' or '''IAC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FOLFIRI regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colorectal cancer
| [[Idarubicin]] x 3 days plus Ara-C ([[cytarabine]]) x 7 days, a variant of classical [[7+3 regimen|7+3]] regimen
| [[Acute myelogenous leukemia]], excluding [[acute promyelocytic leukemia]]
|-
|-
| '''ICE''' <ref name="pmid10577849">{{cite journal |author=Moskowitz CH, Bertino JR, Glassman JR, ''et al.'' |title=Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma |journal=J. Clin. Oncol. |volume=17 |issue=12 |pages=3776–85 |year=1999 |month=December |pmid=10577849 |doi= |url=}}</ref>'
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FOLFIRINOX regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Pancreatic cancer
| Ifosfamide, carboplatin, etopiside
| Relapsed or primary refractory [[non-Hodgkin lymphoma]]
|-
|-
| '''ICE-R'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[FOLFOX regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colorectal cancer
| ICE + [[rituximab]]  
| Relapsed or primary refractory [[non-Hodgkin lymphoma]]
|-
|-
| '''IFL''' <ref name="pmid11006366">{{cite journal |author=Saltz LB, Cox JV, Blanke C, ''et al.'' |title=Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group |journal=N. Engl. J. Med. |volume=343 |issue=13 |pages=905–14 |year=2000 |month=September |pmid=11006366 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[GemOx regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Biliary adenocarcinoma, Pancreatic cancer, Hepatocellular cancer, Testicular cancer
| [[Irinotecan]], [[bolus fluorouracil]] and leucovorin
| Metastatic [[Colorectal cancer|colorectal cancer]]
|-
|-
| '''m-BACOD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[GemOx-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Methotrexate]], [[bleomycin]], doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dexamethasone ([[Decadron]])
| [[Non-Hodgkin lymphoma]]
|-
|-
| '''MACOP-B''' <ref name="pmid2580468">{{cite journal |author=Klimo P, Connors JM |title=MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma |journal=Ann. Intern. Med. |volume=102 |issue=5 |pages=596–602 |year=1985 |month=May |pmid=2580468 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[GVD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkins lymphoma
| [[Methotrexate]], [[leucovorin]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[vincristine]] (Oncovin), [[prednisone]], [[bleomycin]]
| Non-Hodgkin lymphoma
|-
|-
| '''MINE'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[HYPER-CVAD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma, diffuse large B-cell lymphoma, Burkitt's lymphoma
| [[Mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]]
| [[Non-Hodgkin's lymphoma]] and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
|-
|-
| '''MINE-R''' or '''R-MINE'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[IA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
| [[Mesna]], [[ifosfamide]], [[novantrone]], [[etoposide]] plus [[rituximab]]
| [[Non-Hodgkin's lymphoma]] and [[Hodgkin lymphoma]] in [[relapse]] or [[refractoriness|refractory]] cases
|-
|-
| '''Mini-BEAM''' <ref name="pmid7844600">{{cite journal |author=Colwill R, Crump M, Couture F, ''et al.'' |title=Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation |journal=J. Clin. Oncol. |volume=13 |issue=2 |pages=396–402 |year=1995 |month=February |pmid=7844600 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[IAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
| Carmustine (BCNU), etopiside, cytarabine (Ara-C), melphalan
| Hodgkin's lymphoma ([[Salvage therapy]], pre-[[Stem cell transplantation|transplant]])
|-
|-
| '''[[MOPP (medicine)|MOPP]]'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ICE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma, Hodgkin's lymphoma
| [[Mechlorethamine]], [[vincristine]] ([[oncovin]]), [[procarbazine]], [[prednisone]]
| [[Hodgkin's lymphoma]]
|-
|-
| '''MVAC''' <ref name="pmid11001674">{{cite journal |author=von der Maase H, Hansen SW, Roberts JT, ''et al.'' |title=Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study |journal=J. Clin. Oncol. |volume=18 |issue=17 |pages=3068–77 |year=2000 |month=September  pmid=11001674 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ICE-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| Methotrexate, vinblastine, doxorubicin, cisplatin
| [[Bladder cancer]]
|-
|-
| '''NABTT''' <ref name="pmid11835382">{{cite journal |author=Herrlinger U, Schabet M, Brugger W, ''et al.'' |title=German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma |journal=Ann. Neurol. |volume=51 |issue=2 |pages=247–52 |year=2002 |month=February |pmid=11835382 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Ida-FLAG regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Myelodysplastic syndromes and Acute myeloid leukaemia
| Methotrexate, calcium leucovorin; methotrexate, calcium leucovorin; methotrexate, calcium leucovorin
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
|-
|-
| '''PCV''' <ref name="pmid7407756">{{cite journal |author=Levin VA, Edwards MS, Wright DC, ''et al.'' |title=Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors |journal=Cancer Treat Rep |volume=64 |issue=2-3 |pages=237–44 |year=1980 |pmid=7407756 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[IFL regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Colorectal cancer
| [[Procarbazine]], [[lomustine]] (CCNU), [[vincristine]]
| [[Brain tumors]]
|-
|-
| '''ProMACE-MOPP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[LR-CHOP-21 regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Methotrexate]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]] + [[MOPP (medicine)|MOPP]]
| Non-Hodgkin lymphoma
|-
|-
| '''ProMACE-CytaBOM'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[m-BACOD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Prednisone]], [[doxorubicin]] ([[adriamycin]]), [[cyclophosphamide]], [[etoposide]], [[cytarabine]], [[bleomycin]], [[vincristine ]](Oncovin), [[methotrexate]], [[leucovorin]]
| [[Non-Hodgkin lymphoma]]
|-
|-
| '''RdC''' or '''RCD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MACOP-B regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Lenalidomide]] (Revlimid), [[dexamethasone]], [[cyclophosphamide]]
| [[Multiple myeloma]]
|-
|-
| '''R-DHAOx''' <ref name="urlScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MCOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
in previously treated patients with follicular non-Hodgkins lymphoma">{{cite web |url=http://dx.doi.org/10.1016/j.biopha.2009.11.001 |title=ScienceDirect - Biomedicine & Pharmacotherapy : Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma |format= |work= |accessdate=}}</ref>
| Rituximab, dexamethasone, high-dose cytarabine, [[oxaliplatin]]
| Previously treated [[follicular lymphoma]]
|-
|-
| '''R-FCM'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MINE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma, Hodgkin's lymphoma
| [[Rituximab]], [[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]]
| [[B cell]] non-Hodgkin lymphoma
|-
|-
| '''RTOG 93-10''' <ref name="pmid12488408">{{cite journal |author=DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ |title=Combination chemotherapy and radiotherapy for primary central nervous system
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MINE-R regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma, Hodgkin's lymphoma
| lymphoma: Radiation Therapy Oncology Group Study 93-10 |journal=J. Clin. Oncol. |volume=20 |issue=24 |pages=4643–8 |year=2002 |month=December |pmid=12488408 |doi= |url=}}</ref>
| Methotrexate, Leucovorin, vincristine, procarbazine, methotrexate, Leucovorin
| [[Primary central nervous system lymphoma|Primary CNS lymphoma]]
|-
|-
| '''RVD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Mini-BEAM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Lenalidomide]] (Revlimid), [[bortezomib]] (Velcade), [[dexamethasone]]
| [[Multiple myeloma]]
|-
|-
| '''SMILE'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Mito-FLAG regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Acute myelogenous leukemia
| Steroid (dexamethasone/prednisolone), methotrexate, ifosfamide, L-asparaganase, etopisode
| Advanced refractory NK/T-cell lymphoma and leukemia
|-
|-
| '''[[Stanford V]]''' <ref name="pmid7537796">{{cite journal |author=Bartlett NL, Rosenberg SA, Hoppe RT, Hancock SL, Horning SJ |title=Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report |journal=J. Clin. Oncol. |volume=13 |issue=5 |pages=1080–8 |year=1995 |month=May |pmid=7537796 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MOPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Doxorubicin]] ([[Adriamycin]]), [[mechlorethamine]], [[bleomycin]], vinblastine, vincristine (Oncovin), etoposide ([[VP-16]]), prednisone
| Hodgkin's lymphoma
|-
|-
| '''TAC''' <ref name="pmid11208821">{{cite journal |author=Nabholtz JM, Mackey JR, Smylie M, ''et al.'' |title=Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer |journal=J. Clin. Oncol. |volume=19 |issue=2 |pages=314–21 |year=2001 |month=January |pmid=11208821 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[MVAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Bladder cancer
| Docetaxel, doxorubicin, cyclophosphamide
| Metastatic breast cancer
|-
|-
| '''TAP''' <ref name="pmid15169803">{{cite journal |author=Fleming GF, Brunetto VL, Cella D, ''et al.'' |title=Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study |journal=J. Clin. Oncol. |volume=22 |issue=11 |pages=2159–66 |year=2004 |month=June |pmid=15169803 |doi=10.1200/JCO.2004.07.184 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[PCV regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Oligodendroglial tumors
| Paclitaxel, doxorubicin, cisplatin
| [[Endometrial cancer]]
|-
|-
| '''TCH'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[POG 9245 regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
| [[Paclitaxel]] (Taxol), [[carboplatin]], [[trastuzumab]] (Herceptin)
| [[Breast cancer]] with positive [[HER2/neu]] receptor
|-
|-
| '''Thal/Dex'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ProMACE-CytaBOM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Thalidomide]], dexamethasone
| Multiple myeloma
|-
|-
| '''TIP'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[ProMACE-MOPP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma, primary CNS lymphoma
| [[Paclitaxel]] (Taxol), [[ifosfamide]], platinum agent [[cisplatin|cisplatin (Platinol)]]
| [[Testicular cancer]], [[germ cell tumor]]s in salvage therapy
|-
|-
| '''Treanda + Rituxan'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CDOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Bendamustine]], [[Rituximab]]
| Indolent and [[mantle cell lymphoma|mantle cell lymphomas]]
|-
|-
| '''VAC'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CEOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Vincristine]], [[actinomycin]], [[cyclophosphamide]]
| [[Rhabdomyosarcoma]]
|-
|-
| '''VAD'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CHMP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin's lymphoma
| [[Vincristine]], [[Adriamycin]] (doxorubicin), [[dexamethasone]]
| [[Multiple myeloma]]
|-
|-
| '''VAPEC-B'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CHOEP-14 regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| [[Vincristine]], [[doxorubicin]] (Adriamycin), [[prednisone]], [[etoposide]], [[cyclophosphamide]], [[bleomycin]]
| [[Hodgkin's lymphoma]]
|-
|-
| '''VCAP-AMP-VECP''' <ref name="pmid17968021">{{cite journal |author=Tsukasaki K, Utsunomiya A, Fukuda H, ''et al.'' |title=VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801 |journal=J. Clin. Oncol. |volume=25 |issue=34 |pages=5458–64 |year=2007 |month=December |pmid=17968021 |doi=10.1200/JCO.2007.11.9958 |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CHOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| Vincristine, cyclophosphamide, doxorubicin, and prednisone (VCAP)--doxorubicin, [[ranimustine]], and prednisone (AMP)-- [[vindesine]], etoposide, carboplatin, and prednisone (VECP)
| Adult T-cell leukemia-lymphoma (ATLL)
|-
|-
| '''VeIP''' <ref name="pmid9667270">{{cite journal |author=Loehrer PJ, Gonin R, Nichols CR, Weathers T, Einhorn LH |title=Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor |journal=J. Clin. Oncol. |volume=16 |issue=7 |pages=2500–4 |year=1998 |month=July |pmid=9667270 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-CVP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
| Vinblastine, ifosfamide, cisplatin
| [[Testicular cancer]]
|-
|-
| '''VIP''' <ref name="pmid9552027">{{cite journal |author=Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ |title=Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study |journal=J. Clin. Oncol. |volume=16 |issue=4 |pages=1287–93 |year=1998 |month=April |pmid=9552027 |doi= |url=}}</ref>
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-DHAOx regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Follicular lymphoma
| Etopiside, ifosfamide, cisplatin
| [[Testicular cancer]]
|-
|-
| '''VTD-PACE'''
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-EPOCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, HIV-associated lymphoma
| [[Bortezomib]] (Velcade), [[thalidomide]], [[dexamethasone]] plus [[platinum-based antineoplastic|platinum agent]], [[doxorubicin]] (Adriamycin), [[cyclophosphamide]], [[etoposide]]
|-
| [[Multiple myeloma]]
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-ESHAP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-FCM regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Chronic lymphocytic leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-FMC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Chronic lymphocytic leukemia
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-GCVP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-HCVAD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Mantle cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-MA regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Mantle cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R-MINE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma, non-Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[R2CHOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[RCD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-hodgkin lymphoma, CLL
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[RdC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | AL amyloidosis
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[RVD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[SMILE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | NK/T cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Stanford V regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Hodgkin's lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TAP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Endometrial cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TCH regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Breast cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[Thal/Dex regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[TIP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Head and neck cancer, Testicular cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VAC regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Small cell lung cancer
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VAD regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VAPEC-B regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Non-Hodgkin lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VCAP-AMP-VECP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Human T-lymphotropic virus type I-associated Adult T-cell leukemia-lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VeIP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Germ cell tumor
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VIP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Germ cell tumor, Thymoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VR-CHOP regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Diffuse large B-cell lymphoma and Mantle cell lymphoma
|-
| style="font-size: 85%; background: #F5F5F5; padding: 5px;" | [[VTD-PACE regimen]] || style="font-size: 85%; background: #DFE0E1; padding: 5px;" | Multiple myeloma
|}
|}
==References==
{{Reflist|2}}


==External Links==
==External Links==

Latest revision as of 20:19, 4 April 2015

Template:Seealso Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Overview

A chemotherapy regimen is a regimen for chemotherapy defining the drugs to be used, their dosage, the frequency and duration of treatments and other considerations. In modern oncology almost all regimens in use combine several chemotherapy drugs in combination chemotherapy. Acronyms often identify the individual agents used in combination chemotherapy regimens. Unfortunately, the letters used are not consistent across regimens, and in some cases (for example, "BEACOPP") the same letter is used to represent two different treatments. Because of this, there is not a naming standard for chemotherapy regimens, and this page merely represents commonly used conventions.

List of Chemotherapy Regimens

Regimen Indications
7+3 regimen Acute myelogenous leukemia
ABVD regimen Hodgkin's lymphoma
ABVE-PC regimen Hodgkin's lymphoma
AC regimen Breast cancer
ACVBP-R regimen Diffuse large B-cell lymphoma
ADOC regimen Thymoma
BACOD regimen Diffuse large B-cell lymphoma
BEACOPP regimen Hodgkin's lymphoma
BEP regimen Ovarian and testicular germ-cell tumors
CA regimen Breast cancer
CAF regimen Breast cancer
CAPOX regimen Colorectal cancer
CAV regimen Small cell lung cancer
CBV regimen Acute leukemia
CDOP regimen Diffuse large B-cell lymphoma
CEOP-R regimen Diffuse large B-cell lymphoma
CEPP regimen Hodgkin's lymphoma
ChlVPP-EVA regimen Hodgkin's lymphoma
CHOEP regimen Diffuse large B-cell lymphoma
CHOP regimen Non-Hodgkin's lymphoma
CHOP-R regimen Diffuse large B-cell lymphoma
ClaPD regimen Multiple Myeloma
CMF regimen Breast cancer
CMV regimen Bladder carcinoma
CNOP regimen Non-Hodgkin's lymphoma
CODOX-M/IVAC regimen Burkitt's lymphoma
COP regimen Non-Hodgkin's lymphoma
COPP regimen Hodgkin's lymphoma, Non-Hodgkin's lymphoma
CT regimen Ovarian cancer
CTD regimen Multiple Myeloma
CVAD regimen Multiple Myeloma
CVP regimen Non-Hodgkin's lymphoma
CyBorD regimen Multiple Myeloma, AL amyloidosis
DA-EPOCH regimen Non-Hodgkin's lymphoma
DA-R-EPOCH regimen Non-Hodgkin's lymphoma
DBVE-PC regimen Hodgkin's lymphoma
DCEP regimen Multiple Myeloma
DHAP regimen Hodgkin's lymphoma, Non-Hodgkin's lymphoma
DHAX-R regimen Non-Hodgkin's lymphoma
DICE regimen Non-Hodgkin's lymphoma
DT-PACE regimen Multiple Myeloma
EC regimen Small cell lung cancer
ECF regimen Gastric cancer
EOX regimen Oesophageal cancer
EP regimen Small cell lung cancer
EPOCH regimen Non-Hodgkin's lymphoma
EPOCH-R regimen Non-Hodgkin's lymphoma
ESHAP regimen Hodgkin's lymphoma, Non-Hodgkin's lymphoma
ESHAP-R regimen Hodgkin's lymphoma, Non-Hodgkin's lymphoma
FAM regimen Gastric cancer, Pancreatic cancer
FCM regimen Non-Hodgkin's lymphoma, Mantle cell lymphoma
FCM-R regimen Chronic lymphocytic leukemia
FEC regimen Breast cancer
FL regimen Colon cancer
FLAG regimen Acute myeloid leukemia
FLAG-Ida regimen Myelodysplastic syndromes and Acute myeloid leukaemia
FLAG-Mito regimen Acute myelogenous leukemia
FLAMSA regimen Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
FLAMSA-BU regimen Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
FLAMSA-MEL regimen Myelodysplastic syndrome, acute myelogenous leukemia secondary to MDS
FM regimen Non-hodgkin lymphoma
FMC regimen Chronic lymphocytic leukaemia
FMC-R regimen Non-Hodgkin lymphoma, mantle cell lymphoma, CLL
FMR regimen Non-hodgkin lymphoma
FN-D regimen Non-Hodgkin's lymphoma
FOLFIRI regimen Colorectal cancer
FOLFIRINOX regimen Pancreatic cancer
FOLFOX regimen Colorectal cancer
GemOx regimen Biliary adenocarcinoma, Pancreatic cancer, Hepatocellular cancer, Testicular cancer
GemOx-R regimen Non-Hodgkin's lymphoma
GVD regimen Hodgkins lymphoma
HYPER-CVAD regimen Multiple myeloma, diffuse large B-cell lymphoma, Burkitt's lymphoma
IA regimen Acute myelogenous leukemia
IAC regimen Acute myelogenous leukemia
ICE regimen Non-Hodgkin's lymphoma, Hodgkin's lymphoma
ICE-R regimen Non-Hodgkin's lymphoma
Ida-FLAG regimen Myelodysplastic syndromes and Acute myeloid leukaemia
IFL regimen Colorectal cancer
LR-CHOP-21 regimen Non-Hodgkin's lymphoma
m-BACOD regimen Non-Hodgkin's lymphoma
MACOP-B regimen Non-Hodgkin's lymphoma
MCOP regimen Non-Hodgkin's lymphoma
MINE regimen Non-Hodgkin's lymphoma, Hodgkin's lymphoma
MINE-R regimen Non-Hodgkin's lymphoma, Hodgkin's lymphoma
Mini-BEAM regimen Hodgkin's lymphoma
Mito-FLAG regimen Acute myelogenous leukemia
MOPP regimen Hodgkin's lymphoma
MVAC regimen Bladder cancer
PCV regimen Oligodendroglial tumors
POG 9245 regimen Hodgkin's lymphoma
ProMACE-CytaBOM regimen Non-Hodgkin's lymphoma
ProMACE-MOPP regimen Diffuse large B-cell lymphoma, primary CNS lymphoma
R-CDOP regimen Non-Hodgkin's lymphoma
R-CEOP regimen Diffuse large B-cell lymphoma
R-CHMP regimen Non-Hodgkin's lymphoma
R-CHOEP-14 regimen Diffuse large B-cell lymphoma
R-CHOP regimen Diffuse large B-cell lymphoma
R-CVP regimen Diffuse large B-cell lymphoma
R-DHAOx regimen Follicular lymphoma
R-EPOCH regimen Hodgkin's lymphoma, HIV-associated lymphoma
R-ESHAP regimen Diffuse large B-cell lymphoma
R-FCM regimen Chronic lymphocytic leukemia
R-FMC regimen Chronic lymphocytic leukemia
R-GCVP regimen Diffuse large B-cell lymphoma
R-HCVAD regimen Mantle cell lymphoma
R-MA regimen Mantle cell lymphoma
R-MINE regimen Hodgkin's lymphoma, non-Hodgkin's lymphoma
R2CHOP regimen Diffuse large B-cell lymphoma
RCD regimen Non-hodgkin lymphoma, CLL
RdC regimen AL amyloidosis
RVD regimen Multiple myeloma
SMILE regimen NK/T cell lymphoma
Stanford V regimen Hodgkin's lymphoma
TAC regimen Breast cancer
TAP regimen Endometrial cancer
TC regimen Breast cancer
TCH regimen Breast cancer
Thal/Dex regimen Multiple myeloma
TIP regimen Head and neck cancer, Testicular cancer
VAC regimen Small cell lung cancer
VAD regimen Multiple myeloma
VAPEC-B regimen Non-Hodgkin lymphoma
VCAP-AMP-VECP regimen Human T-lymphotropic virus type I-associated Adult T-cell leukemia-lymphoma
VeIP regimen Germ cell tumor
VIP regimen Germ cell tumor, Thymoma
VR-CHOP regimen Diffuse large B-cell lymphoma and Mantle cell lymphoma
VTD-PACE regimen Multiple myeloma

External Links